GenVec Inc (NASDAQ:GNVC) was the recipient of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 244,582 shares, a decline of 2.2% from the April 28th total of 250,068 shares. Based on an average trading volume of 35,385 shares, the short-interest ratio is presently 6.9 days.

Several institutional investors have recently added to or reduced their stakes in GNVC. Perceptive Advisors LLC acquired a new position in GenVec during the fourth quarter valued at about $180,000. Geode Capital Management LLC increased its position in GenVec by 10.8% in the first quarter. Geode Capital Management LLC now owns 17,218 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 1,675 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in GenVec by 37.1% in the first quarter. Vanguard Group Inc. now owns 25,745 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 6,973 shares during the last quarter.

Shares of GenVec (NASDAQ GNVC) opened at 6.59 on Friday. The firm’s market cap is $14.98 million. GenVec has a 12-month low of $0.27 and a 12-month high of $10.44. The firm’s 50-day moving average is $6.54 and its 200-day moving average is $5.35.

TRADEMARK VIOLATION WARNING: “GenVec Inc (GNVC) Short Interest Update” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/06/04/genvec-inc-gnvc-short-interest-update.html.

About GenVec

GenVec, Inc (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria.

Receive News & Ratings for GenVec Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec Inc and related companies with MarketBeat.com's FREE daily email newsletter.